InvestorsHub Logo
icon url

CalMustang

08/19/19 3:02 PM

#209857 RE: Atom0aks #209855

Oliciderine.
icon url

sts66

08/20/19 3:19 PM

#210068 RE: Atom0aks #209855

Anything related to Monsanto.....I can't list most of the ones I'm aware of, they're OT and political scandals.....Levaquin is a horrible example of FDA hiding risks of an antibiotic so JNJ could continue to reap profits until patent protection ran out:

https://www.angeloslaw.com/personal-injury/pharmaceutical-liability/levaquin/


In 2016 FDA finally said fluoroquinolones should only be used as antibiotic of last resort, but it was way too late for thousand of patients who suffered permanent disabilities, including me - this class of drugs works by damaging the DNA of bacteria, and guess what - they damage human DNA too.

https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics

Fluoroquinolones are antibiotics that kill or stop the growth of bacteria. While these drugs are effective in treating serious bacterial infections, an FDA safety review found that both oral and injectable fluroquinolones are associated with disabling side effects involving tendons, muscles, joints, nerves and the central nervous system. These side effects can occur hours to weeks after exposure to fluoroquinolones and may potentially be permanent.

Because the risk of these serious side effects generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections, the FDA has determined that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options. For some serious bacterial infections, including anthrax, plague and bacterial pneumonia among others, the benefits of fluoroquinolones outweigh the risks and it is appropriate for them to remain available as a therapeutic option.




JNJ is being sued by so many people injured by Levaquin that they voluntarily pulled it off the market.